ASX:RAC

Race Oncology (RAC) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
76,322 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RAC stock logo

About Race Oncology Stock (ASX:RAC)

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

RAC Stock News Headlines

Will Race Oncology (ASX:RAC) Spend Its Cash Wisely?
War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
War Over Taiwan? Protect Your Wealth NOW
With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.
See More Headlines
Receive RAC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2019
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-11,170,000.00
Net Margins
-192.15%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.82 million
Book Value
A$0.12 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.37
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Daniel Tillett
    Chief Executive Officer
  • Dr. Peter M. Smith Ph.D. (Age 61)
    Executive Director
    Comp: $635
  • Ms. Christina Manfre
    Chief Financial Officer
  • Prof. Tim Hammond
    Interim Chief Scientific Officer
  • Dr. Michelle Rashford
    Chief Medical Officer
  • Mr. Peter Gordon Webse B.Bus (Age 61)
    FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary

RAC Stock Analysis - Frequently Asked Questions

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) released its earnings results on Wednesday, February, 27th. The company reported ($0.03) earnings per share for the quarter. Race Oncology had a negative net margin of 192.15% and a negative trailing twelve-month return on equity of 43.67%.

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX).

This page (ASX:RAC) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners